​Route 92 Medical has announced the publication of initial results from the SUMMIT NZ clinical trial—a single-arm, multicentre, prospective trial evaluating its proprietary Monopoint operating platform.

Results from the first 45 patients demonstrated that the Monopoint platform yielded an 80% first-pass effect with primary use of the HiPoint 88 (0.088-inch internal diameter [ID]) catheter, which is a super-bore catheter designed to consistently reach the proximal middle cerebral artery (MCA). The Route 92 HiPoint 88 aspiration catheter successfully reached the proximal MCA (M1 segment) in 100% of the cases attempted, as per a company press release. These results have been published online in the Journal of NeuroInterventional Surgery.

“The Monopoint operating platform with HiPoint 88 catheters delivered a step change in first-pass efficacy in the SUMMIT NZ trial, signalling clear potential for improved patient outcomes given the importance of clearing thrombus to save time and save brain,” said James Caldwell (Auckland City Hospital, Auckland, New Zealand), the paper’s first author. “The platform is designed to improve catheter deliverability, offering the advantage of greater simplicity for the operating physician to efficiently perform thrombectomy for patients.”

Read More: ​​https://neuronewsinternational.com/route-92-publishes-data-demonstrating-80-first-pass-effect-with-novel-thrombectomy-system/

SAN MATEO, Calif., June 06, 2022 -- Route 92 Medical, Inc., a private medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the publication of initial results of the SUMMIT NZ clinical trial, a single-arm, multi-center, prospective trial evaluating the proprietary Monopoint operating platform. Results from the first 45 patients demonstrated that the Monopoint platform yielded an 80% first pass effect (FPE1) with primary use of the HiPoint™ 88 (.088in ID) catheter, a super-bore catheter designed to consistently reach the proximal middle cerebral artery (MCA). The Route 92 HiPoint 88 aspiration catheter successfully reached the proximal MCA (M1 segment) in 100% of the cases attempted. The results were published in the Journal of NeuroInterventional Surgery online2.

“The Monopoint operating platform with HiPoint 88 catheters delivered a step change in first pass efficacy in the SUMMIT NZ trial, signaling clear potential for improved patient outcomes given the importance of clearing thrombus to save time and save brain,” said Dr. James Caldwell, attending physician at Auckland City Hospital and the paper’s first author. “The platform is designed to improve catheter deliverability offering the advantage of greater simplicity for the operating physician to efficiently perform thrombectomy for patients.”

Read More: www.bakersfield.com/ap/news/route-92-medical-announces-publication-of-initial-summit-nz-clinical-trial-results/article_81496d9f-0f57-55e5-87ed-aead22a4883c.html

Chronic musculoskeletal pain has a vast global prevalence and economic burden. Conservative therapies are universally recommended but require patient engagement and self-management to be effective. This study aimed to evaluate the efficacy of a 12-week digital care program (DCP) in a large population of patients with chronic knee and back pain.
... ...
​A longitudinal observational study was conducted using a remote DCP available through a mobile app. Subjects participated in a 12-week multimodal DCP incorporating education, sensor-guided exercise therapy (ET), and behavioral health support with 1-on-1 remote health coaching. The primary outcome was pain measured by the visual analog scale (VAS). Secondary measures included engagement levels, program completion, program satisfaction, condition-specific pain measures, depression, anxiety, and work productivity.


A total of 10,264 adults with either knee (n=3796) or low back (n=6468) pain for at least three months were included in the study. Participants experienced a 68.45% average improvement in VAS pain between baseline intake and 12 weeks. In all, 73.04% (7497/10,264) participants completed the DCP into the final month.

78.60% (5893/7497) of program completers (7144/10,264, 69.60% of all participants) achieved minimally important change in pain. The number of ET sessions and coaching interactions were both positively associated with improvement in pain, suggesting that the amount of engagement influenced outcomes.

Read More: ​https://www.hingehealth.com/10000-participant-clinical-study/

SUNNYVALE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the Centers for Medicare and Medicaid Services (CMS), through collaboration with the Society of Vascular Surgery’s Patient Safety Organization (SVS PSO) and their Vascular Quality Initiative (VQI), has expanded coverage for TCAR to include standard surgical risk patients within the VQI’s TCAR Surveillance Project (TSP). This decision is effective immediately and comes on the heels of the recent Food and Drug Administration (FDA) approval for expanded indications for the ENROUTE® Transcarotid Stent System to include patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA).

“This CMS coverage expansion ensures that many more carotid artery disease patients who require treatment have the opportunity to benefit from the minimally invasive approach that our TCAR® system offers,” said Erica Rogers, President and Chief Executive Officer of Silk Road Medical. “We’re grateful to the teams at the FDA, CMS, and SVS for their valuable collaboration and partnership in recognizing the weight of real-world evidence supporting TCAR use in this expanded patient population and the necessity of working to prevent the debilitating impacts of stroke on individuals, their families, and the health system as a whole.”

Read More: ​https://www.globenewswire.com/news-release/2022/06/02/2455019/0/en/Silk-Road-Medical-Announces-Expanded-Medicare-Coverage-for-TCAR-in-Standard-Surgical-Risk-Patients.html

Healthy lifestyle changes, such as eating healthy food, and being active, can help – and now, there are new digital support options like Omada.

A prediabetes diagnosis offers a valuable opportunity to take action to protect your health, according to clinicians. 

“Type 2 diabetes is preventable,” said Dr. Carolyn Jasik, chief medical officer of Omada Health, a digital tool that helps individuals make behavioral changes that improve their health. “Patients who embrace lifestyle changes have a good shot at never developing diabetes.” 

Read More: ​https://coverage.bluecrossma.com/article/taking-action-prediabetes

Wei-Li Shao, president of Omada Health, provides insight on financial trends in digital health investment, and what the virtual-first care approach means for the future of health care.

Welcome back to PopHealth Perspectives. A conversation with the Population Health Learning Network, where we combine expert commentary and exclusive insight into key issues in population health management and more.

Today, we are joined by Wei-Li Shao, President of Omada Health. He provides insight on financial trends in digital health investment, Omada's platform and funding, and what the virtual first care approach means for the future of health care.

Read More: ​https://www.hmpgloballearningnetwork.com/site/ihe/podcasts/financial-trends-digital-health-future-virtual-first-care